Cargando…
A plasma protein signature associated with cognitive function in men without severe cognitive impairment
BACKGROUND: A minimally invasive blood-based assessment of cognitive function could be a promising screening strategy to identify high-risk groups for the incidence of Alzheimer’s disease. METHODS: The study included 448 cognitively unimpaired men (mean age 64.1 years) drawn from the Geelong Osteopo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472730/ https://www.ncbi.nlm.nih.gov/pubmed/37658429 http://dx.doi.org/10.1186/s13195-023-01294-7 |
_version_ | 1785100144179412992 |
---|---|
author | Mehta, Kanika Mohebbi, Mohammadreza Pasco, Julie A. Williams, Lana J. Sui, Sophia X. Walder, Ken Ng, Boon Lung Gupta, Veer Bala |
author_facet | Mehta, Kanika Mohebbi, Mohammadreza Pasco, Julie A. Williams, Lana J. Sui, Sophia X. Walder, Ken Ng, Boon Lung Gupta, Veer Bala |
author_sort | Mehta, Kanika |
collection | PubMed |
description | BACKGROUND: A minimally invasive blood-based assessment of cognitive function could be a promising screening strategy to identify high-risk groups for the incidence of Alzheimer’s disease. METHODS: The study included 448 cognitively unimpaired men (mean age 64.1 years) drawn from the Geelong Osteoporosis Study. A targeted mass spectrometry-based proteomic assay was performed to measure the abundance levels of 269 plasma proteins followed by linear regression analyses adjusted for age and APOE ε4 carrier status to identify the biomarkers related to overall cognitive function. Furthermore, two-way interactions were conducted to see whether Alzheimer’s disease-linked genetic variants or health conditions modify the association between biomarkers and cognitive function. RESULTS: Ten plasma proteins showed an association with overall cognitive function. This association was modified by allelic variants in genes ABCA7, CLU, BDNF and MS4A6A that have been previously linked to Alzheimer’s disease. Modifiable health conditions such as mood disorders and poor bone health, which are postulated to be risk factors for Alzheimer’s disease, also impacted the relationship observed between protein marker levels and cognition. In addition to the univariate analyses, an 11-feature multianalyte model was created using the least absolute shrinkage and selection operator regression that identified 10 protein features and age associated with cognitive function. CONCLUSIONS: Overall, the present study revealed plasma protein candidates that may contribute to the development of a blood-based screening test for identifying early cognitive changes. This study also highlights the importance of considering other risk factors in elucidating the relationship between biomarkers and cognition, an area that remains largely unexplored. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01294-7. |
format | Online Article Text |
id | pubmed-10472730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104727302023-09-02 A plasma protein signature associated with cognitive function in men without severe cognitive impairment Mehta, Kanika Mohebbi, Mohammadreza Pasco, Julie A. Williams, Lana J. Sui, Sophia X. Walder, Ken Ng, Boon Lung Gupta, Veer Bala Alzheimers Res Ther Research BACKGROUND: A minimally invasive blood-based assessment of cognitive function could be a promising screening strategy to identify high-risk groups for the incidence of Alzheimer’s disease. METHODS: The study included 448 cognitively unimpaired men (mean age 64.1 years) drawn from the Geelong Osteoporosis Study. A targeted mass spectrometry-based proteomic assay was performed to measure the abundance levels of 269 plasma proteins followed by linear regression analyses adjusted for age and APOE ε4 carrier status to identify the biomarkers related to overall cognitive function. Furthermore, two-way interactions were conducted to see whether Alzheimer’s disease-linked genetic variants or health conditions modify the association between biomarkers and cognitive function. RESULTS: Ten plasma proteins showed an association with overall cognitive function. This association was modified by allelic variants in genes ABCA7, CLU, BDNF and MS4A6A that have been previously linked to Alzheimer’s disease. Modifiable health conditions such as mood disorders and poor bone health, which are postulated to be risk factors for Alzheimer’s disease, also impacted the relationship observed between protein marker levels and cognition. In addition to the univariate analyses, an 11-feature multianalyte model was created using the least absolute shrinkage and selection operator regression that identified 10 protein features and age associated with cognitive function. CONCLUSIONS: Overall, the present study revealed plasma protein candidates that may contribute to the development of a blood-based screening test for identifying early cognitive changes. This study also highlights the importance of considering other risk factors in elucidating the relationship between biomarkers and cognition, an area that remains largely unexplored. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01294-7. BioMed Central 2023-09-01 /pmc/articles/PMC10472730/ /pubmed/37658429 http://dx.doi.org/10.1186/s13195-023-01294-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mehta, Kanika Mohebbi, Mohammadreza Pasco, Julie A. Williams, Lana J. Sui, Sophia X. Walder, Ken Ng, Boon Lung Gupta, Veer Bala A plasma protein signature associated with cognitive function in men without severe cognitive impairment |
title | A plasma protein signature associated with cognitive function in men without severe cognitive impairment |
title_full | A plasma protein signature associated with cognitive function in men without severe cognitive impairment |
title_fullStr | A plasma protein signature associated with cognitive function in men without severe cognitive impairment |
title_full_unstemmed | A plasma protein signature associated with cognitive function in men without severe cognitive impairment |
title_short | A plasma protein signature associated with cognitive function in men without severe cognitive impairment |
title_sort | plasma protein signature associated with cognitive function in men without severe cognitive impairment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472730/ https://www.ncbi.nlm.nih.gov/pubmed/37658429 http://dx.doi.org/10.1186/s13195-023-01294-7 |
work_keys_str_mv | AT mehtakanika aplasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT mohebbimohammadreza aplasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT pascojuliea aplasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT williamslanaj aplasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT suisophiax aplasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT walderken aplasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT ngboonlung aplasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT guptaveerbala aplasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT mehtakanika plasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT mohebbimohammadreza plasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT pascojuliea plasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT williamslanaj plasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT suisophiax plasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT walderken plasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT ngboonlung plasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment AT guptaveerbala plasmaproteinsignatureassociatedwithcognitivefunctioninmenwithoutseverecognitiveimpairment |